Apoptosis of tumoral and nontumoral lymphoid cells is induced by both mdm2 and p53 antisense oligodeoxynucleotides

Blood

Volumn 97, Issue 4, 2001, Pages 1043-1049

  Capoulade, C ^a   Mir, L M ^a   Carlier, K ^a   Lecluse Y ^a   Tetaud C ^a   Mishal, Z ^a   Wiels, J ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE; PROTEIN MDM2; PROTEIN P53;

APOPTOSIS; ARTICLE; BURKITT LYMPHOMA; CELL PROLIFERATION; CONTROLLED STUDY; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; LYMPHOID CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR SUPPRESSOR GENE;

EID: 0035865516     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V97.4.1043     Document Type: Article

References (59)

1. The p53 pathway
2. An insight into the life of p53: A protein coping with many functions! Review of the 9th p53 Workshop, Crete, May 9-13, 1998
3. Regulation of p53 downstream genes
4. Mutations in the p53 tumor suppressor gene: Clues to cancer etiology and molecular pathogenesis
5. IARC database of p53 gene mutations in human tumors and cell lines: Updated compilation, revised formats and new visualisation tools
6. Molecular analysis and chromosomal mapping of amplified genes isolated from a transformed mouse 3T3 cell line
7. Tumorigenic potential associated with enhanced expression of a gene that is amplified in a mouse tumor cell line
8. The mdm-2 oncogene can overcome wild-type p53 suppression of transformed cell growth
9. The MDM2 gene amplification database
10. Targeted expression of MDM2 uncouples S phase from mitosis and inhibits mammary gland development independent of p53
11. Overexpression of Mdm2 in mice reveals a p53-independent role for Mdm2 in tumorigenesis
12. Mdm2: Keeping p53 under control
13. The mdm2 proto-oncogene
14. Functions of the MDM2 oncoprotein
15. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation
16. Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53
17. Nucleo-cytoplasmic shuttling of the hdm2 oncoprotein regulates the levels of the p53 protein via a pathway used by the human immunodeficiency virus rev protein
18. Nucleocytoplasmic shuttling of oncoprotein Hdm2 is required for Hdm2-mediated degradation of p53
19. Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53
20. Mdm2 expression is induced by wild-type p53 activity
21. The p53-mdm2 autoregulatory feedback loop
22. Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53
23. Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53
24. The pathogenesis of Burkitt's lymphoma
25. c-myc deregulation by chromosomal translocation in Burkitt's lymphoma
26. Chromosomal abnormalities in adult non-endemic Burkitt's lymphoma and leukemia: 22 New reports and a review of 148 cases from the literature
27. p53 in hematologic malignancies
28. Mutant p53 detected in a majority of Burkitt lymphoma cell lines by monoclonal antibody PAb240
29. p53 is frequently mutated in Burkitt's lymphoma cell lines
30. Biological activities of p53 mutants in Burkitt's lymphoma cells
31. Intraclonal molecular heterogeneity suggests a hierarchy of pathogenetic events in Burkitt's lymphoma
32. Overexpression of MDM2, due to enhanced translation, results in inactivation of wild-type p53 in Burkitt's lymphoma cells
33. Transformation of rat cells by DNA of human adenovirus 5
34. Stimulation of E2F1/DP1 transcriptional activity by MDM2 oncoprotein
35. Amplification of a gene encoding a p53-associated protein in human sarcomas
36. The involvement of "tumor suppressor" p53 in normal and chronic myelogenous leukemia hemopoeisis
37. Rearrangement of the p53 gene in human osteogenic sarcomas
38. Highly efficient oligonucleotide transfer into intact yeast cells using square-wave pulse electroporation
39. Cell electropermeabilization: A new tool for biochemical and pharmacological studies
40. Effective treatment of cutaneous and subcutaneous malignant tumours by electrochemotherapy
41. Antitumor drug delivery by tissue electroporation
42. Importance of poly-(ADP-ribose) polymerase and its cleavage in apoptosis. Lesson from an uncleavable mutant
43. Regulation of p53 stability by Mdm2
44. Mdm2 promotes the rapid degradation of p53
45. Ubiquitous induction of p53 in tumor cells by antisense inhibition of MDM2 expression
46. MDM2 protein overexpression promotes proliferation and survival of multiple myeloma cells
47. ARF promotes MDM2 degradation and stabilizes p53: ARF-INF4a locus deletion impairs both the Rb and p53 tumor suppression pathways
48. RB regulates the stability and the apoptotic function of p53 via MDM2
49. P300/MDM2 complexes participate in MDM2-mediated p53 degradation
50. Design of a synthetic Mdm2-binding mini protein that activates the p53 response in vivo
51. p53 mediated death of cells overexpressing MDM2 by an inhibitor of MDM2 interaction with p53
52. Mdm2 binds p73 alpha without targeting degradation
53. Keeping an old friend under control: Regulation of p53 stability
54. Combination anti-gene therapy targeting c-myc and p53 in ovarian cancer cell lines
55. Inhibition of cell growth mediated by plasmids encoding p53 anti-sense
56. Selective cytotoxicity to human leukemic myeloblasts produced by oligodeoxyribonucleotide phosphorothioates complementary to p53 nucleotide sequences
57. Antisense RNA p53 inhibits proliferation of normal and transformed cells
58. Antisense p53 provokes changes in HeLa cell growth and morphology
59. p53 antisense oligonucleotide inhibits growth of human colon tumor and normal cell lines